<DOC>
	<DOC>NCT02267629</DOC>
	<brief_summary>This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.</brief_summary>
	<brief_title>Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<criteria>Inclusion Criteria for Patients with No medication Washout: Age 1855 Physically healthy and not currently pregnant Primary Diagnosis of OCD currently off all psychotropic medications and other drugs Able to provide informed consent Exclusion Criteria for Patients with No Medication Washout: Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance abuse in prior year[including nicotine], lifetime substance dependence disorder [except nicotine]) Female patients who are either pregnant or nursing Enrolled in or planning to enroll in Cognitive Behavioral Therapy. Medical conditions that make participation unsafe (e.g., high blood pressure, head injury) Currently on medications that make participation unsafe History of allergy, sensitivity, or intolerance to NmethylDaspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, destropropoxyphene, or ketobemidone. Inclusion Criteria for Patients with Medication Washout: Age 1855 Physically healthy and not currently pregnant Primary Diagnosis of OCD Currently on adequate dose of medication for treatment of OCD, but have not achieved at least partial remission and able to handle a medication washout. Able to provide informed consent Exclusion Criteria for Patients with Medication Washout: Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance abuse in prior year[including nicotine], lifetime substance dependence disorder [except nicotine]) Female patients who are either pregnant or nursing Enrolled in or planning to enroll in CognitiveBehavioral Therapy. Patient judged unlikely to be able to tolerated a medication washout. Medical conditions that make participation unsafe (e.g., high blood pressure, head injury) Currently on medications that make participation unsafe History of allergy, sensitivity, or intolerance to NmethylDaspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, destropropoxyphene, or ketobemidone.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OCD</keyword>
</DOC>